RxSight, Inc.

For the period ended Sep 30, 2025. Filed Nov 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 5, 2025

RXST$4.90+0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS (UNAUDITED)

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Sales	$30,340	$35,314	$101,871	$99,713
Cost of sales	6,113	10,094	24,125	29,558
Gross profit	24,227	25,220	77,746	70,155
Operating expenses:
Selling, general and administrative	27,345	25,608	84,956	73,225
Research and development	9,060	8,838	29,644	25,160
Total operating expenses	36,405	34,446	114,600	98,385
Loss from operations	(12,178)	(9,226)	(36,854)	(28,230)
Other income (expense), net:
Interest expense	(4)	(5)	(14)	(16)
Interest and other income	2,376	2,906	7,137	6,767
Loss before income taxes	(9,806)	(6,325)	(29,731)	(21,479)
Income tax expense	10	13	61	38
Net loss	$(9,816)	$(6,338)	$(29,792)	$(21,517)
Other comprehensive loss
Unrealized gain (loss) on short-term investments	178	633	(123)	524
Foreign currency translation (loss) gain	(1)	6	18	2
Total other comprehensive loss	177	639	(105)	526
Comprehensive loss	$(9,639)	$(5,699)	$(29,897)	$(20,991)
Net loss per share:
Basic & diluted	$(0.24)	$(0.16)	$(0.73)	$(0.56)
Weighted-average shares used in computing net loss per share:
Attributable to common stock, basic & diluted	40,965,219	39,788,621	40,741,219	38,367,759

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.